Objective: To document the incidence, natural history and compare neurodevelopmental outcome of newborns with and without frontal horn cysts (FHC).
Introduction
Screening cranial ultrasound scans (CUS) are routinely recommended for all infants born at p32 weeks completed gestational age (GA) or with birth weight (BW) p1500 g to identify lesions such as intraventricular and/or intraparenchymal hemorrhages or periventricular leucomalacia (PVL). 1 The detection of these abnormalities is important for providing appropriate counseling to parents regarding adverse long-term neurodevelopmental outcomes in this fragile population and for enrollment in early infant development programs to reduce the impact of adverse neurological outcomes.
Frontal horn cysts (FHC) is one such condition for which there is limited information regarding the incidence, etiology, natural history and relevance to long-term neurodevelopment outcome. The information is based on case reports and case series. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Further, the use of various terminologies to describe FHC including periventricular pseudocysts or cavitations, coarctation of the lateral ventricle or connatal cyst has resulted in significant heterogeneity in the way these lesions are classified.
The reported incidence varies from 0.5 to 0.9%. 2, 3, [5] [6] [7] [9] [10] [11] FHC are usually thin-walled cysts located at the superolateral angle of the frontal horn of the lateral ventricles, 13 can be unilateral or bilateral, and vary in size, shape and number. 5 They are usually noted on the first CUS and typically disappear over the first year of life. 2, 10 On histopathology, the cysts contain neuroblasts and ependymal cells without any evidence of hemorrhage or distortion of the adjacent architecture. 5 The etiology has been widely speculated varying from being a normal variant to secondary to a viral infection, chromosomal anomaly or post-ischemic or hemorrhagic event. Similarly, the outcomes reported vary from normal neurodevelopment in the majority of the cases to muscle tone abnormalities, cerebral palsy and developmental delay with or without seizures (Table 1) . 2, 3, [5] [6] [7] [9] [10] [11] Discordant results in the literature could be due to biases in research design such as case reports or case series, inclusion of either term or both term and preterm population in most studies, 2, 3, 5, 6, 10, 12 inclusion of infants with other CUS abnormalities without a similar comparator group (controls), number of infants lost to follow-up 2 and the potential confounding effect of preterm gestation on neurodevelopment outcome. In the only case-control study published to date, Wong et al.
11 compared growth and neurodevelopmental outcomes in 10 infants with and without isolated paraventricular cysts. However, two infants each in both groups were excluded in the analysis as outcomes were reported using different neurodevelopmental assessment tools. In the remaining eight cases and controls, no statistically significant differences in terms of growth and neurodevelopmental outcomes were reported. Therefore, to further refine the evidence regarding the incidence, natural history and neurodevelopmental outcome of infants with FHC, we undertook this case-control study at our center. Our objective was to document the incidence, natural history, and compare the neurodevelopmental outcomes of newborns with and without FHC.
Methods
In a case-control study design, newborns with FHC were identified by reviewing all of the CUS performed in the neonatal intensive care unit, Mount Sinai Hospital, Toronto, Ontario, Canada, during the period of January 2000 to December 2005 from the medical imaging database. Control newborn infants with no FHC were then identified from the Department of Paediatrics database for the equivalent time period and matched for GA (±1 week), BW ( ± 100 g), sex and worst CUS finding. When more than one potential control was identified, the infant nearest to the GA and BW was chosen.
In our center, neonatal CUS are performed in all preterm infants p32 weeks gestation and/or BW p1500 g, in the first week of life, then at 1 month of age and every 4 weeks until the infant is discharged from the hospital. In preterm infants at extremely low GA, a CUS is usually performed within 48 to 72 h of birth so as to guide clinical decision-making. For children >32 weeks GA, CUS are performed at the discretion of the attending neonatologist based on clinical indication.
Neonatal CUS were performed with an 8.5 MHz transducer using Philips HDI 5000-C (Philips Healthcare, Bothell, WA, USA). In our center the series of imaging obtained includes coronal, sagittal, parasagittal and temporal views. The CUS were then screened and reported for the presence of FHC. All CUS of the study population were reviewed by one radiologist (SS) to confirm and monitor the (1) Diplegia (3) Death (6) a Rademaker et al.
6
Case series 8 Preterm (5) 0.87 Normal (6) Term (3) Death (2) (17) Death (10) Abbreviations: N, number of cases; NA, not available. a Outcome data from 1 infant who died at 1.9 years was included in the analysis.
Newborn frontal horn cystsprogress of FHC and identification of any other abnormalities. Absence of FHC on the remaining scans was confirmed by radiologist report. The criteria for enrollment in our Neonatal Follow Up program located at the Hospital for Sick Children, Toronto, Ontario, Canada include either BW (<1000 g) or GA (<28 weeks gestation) or at the discretion of the attending neonatologist.
The Neonatal Follow Up assesses hearing, vision, neuromuscular development and neurodevelopment. Hearing screening begins before hospital discharge with an automated auditory brainstem response, which is repeated at 4 months corrected age and is followed with visual reinforcement audiometry at 12 months corrected age. Ophthalmology assessment begins before discharge according to Retinopathy of Prematurity screening guidelines set out by the American Academy of Pediatrics 14 and continues after discharge as needed. A neuromuscular physical examination is performed at each visit to assess for any abnormalities of movement and/or tone. Cognitive outcomes are ascertained between 18 and 24 months. At this time, initial screening includes the Ages and Stages Questionnaire (ASQ) and Receptive-Expressive Emergent Language Scale 2 test. ASQ domains include language, gross motor, fine motor, personal, social and problem-solving. The parent-completed responses on ASQ has been compared against validated psychometric assessment tools including the Griffith Mental Development Scales for 12 and 24 months, Bayley Mental Development Intelligence Scale for 18 months and MCarthy General Cognitive Intelligence Scale for 48 months and found to have the following test characteristics. 15 The ASQ has a sensitivity of 90%, a negative predictive value of 98% and a under-referral rate of 1%, suggesting that it a useful screening tool for cognitive and motor delays. The Receptive-Expressive Emergent Language Scale 2 is a test to assess language development (receptive and expressive) for children between 0 and 3 years with a reliability score of 0.95 to 0.98 depending on the age of the child. 16 Adverse neurodevelopmental outcome for the purposes of this study was defined as delay by X2 standard deviation (s.d.) below the mean for age. If at the 18-to 24-month visit, a patient scored below the mean in any of the domains other than gross motor, they were referred for further assessment using the Bayley Scale of Infant Development II (BSID II).
Using a standardized form, we collected data on maternal and infant characteristics, all CUS results until discharge and neurodevelopmental assessment. Statistical analyses were performed using the Statistical Package for the Social Sciences software (version 17; Chicago, IL, USA). Demographic characteristics and neurodevelopmental outcomes were compared between groups using w 2 -test or Fisher's exact test of association for categorical data and Student's t-test for continuous data. A P-value of <0.05 was considered statistically significant. Results are presented as mean (s.d.), median (range) or absolute numbers (percentages) as appropriate.
The research ethics boards of Mount Sinai Hospital and The Hospital for Sick Children approved the study.
Results
During the 6-year study period, 30 infants with FHC were identified from the medical imaging database. The mean (s.d.) GA at birth for the infants with FHC was 29.5 (3.5) weeks with a range from 25 to 38 weeks. Twenty-five of these cases occurred in preterm infants p32 weeks gestation. During the study period, 2340 preterm infants p32 weeks gestation were admitted to our neonatal intensive care unit, giving an incidence of unilateral or bilateral FHC of 1% (25 of 2340) in this cohort. There was a slight preponderance of FHC diagnosed in male patients (56%). Of infants with FHC, 27% were multiples and of these patients, the finding was consistent in at least two of the sibling pairs 75% of the time. Figure 1 depicts the typical appearance of multiple FHC in sagittal view. Infants with FHC had a distinctive morphology with the cysts appearing to be thin-walled fluid-filled structures adjacent to the anterior most aspect of the frontal horns of the lateral ventricle. In all but two cases, the FHC was present on the initial CUS and persisted on all subsequent scans until the time of discharge. The FHC were bilateral in 43% of the cases. Of the unilateral cases, 76% were on the left. There was great variability in both number and size of cysts throughout this population with a range of 1 to 6 cysts per patient and a range of size from 1 to 18 mm. The cysts did not change in number or size throughout the period of observation.
In subjects with FHC, additional CUS findings identified were as follows: choroid plexus cysts (N ¼ 1), germinal matrix hemorrhage or cyst (N ¼ 8) and bilateral grade III hemorrhage (N ¼ 1). The remainder of the CUS were normal (N ¼ 20).
Of the 30 patients with FHC, 17 met the criteria for enrollment in Neonatal Follow Up clinic of which 1 patient was lost to follow-up. Thirteen patients did not meet the eligibility criteria for enrollment in Neonatal Follow Up as they were >32 weeks gestation. The neurodevelopmental outcome is not available for these patients. The maternal and neonatal characteristics for newborns with and without FHC (N ¼ 16 in each group) are presented in Tables 2 and 3 . There were no statistically significant differences between groups (P>0.05 for all variables). All these infants were inborn.
The neurodevelopmental outcomes are presented in Table 4 . There were no statistically significant differences in the rate of language delay (communication), fine motor, gross motor, personal, social or problem-solving skills between groups as assessed by ASQ (P>0.05 for all outcomes). None of the participants had cerebral palsy. Hearing impairment was noted in three patients with FHC; mild hearing loss in one and hearing impairment with need for hearing aids in the other two. There were no cases of hearing impairment among the controls. Visual problems were noted in one infant in both groups (required prescription glasses). Five infants (N ¼ 3 in the FHC group and N ¼ 2 in the no FHC group) also had neurodevelopmental assessment using BSID II. Of the three cases of FHC with abnormalities in ASQ domain, two were reported to have a normal BSID II whereas one had mild delay (psychomotor developmental index of 70 to 85). Two cases with no FHC had abnormalities in ASQ domains, however in both the BSID II scores were normal.
Discussion
In our study, the incidence of unilateral or bilateral FHC was noted to be 1% in preterm infants p32 weeks gestation, which is consistent with reported incidence in the literature (range 0.48 to 0.9%). 2, 3, 5, 6, 9, 12 However, the incidence in infants >32 weeks could not be quantified as they were not routinely subjected to CUS. Further, in this largest case-control study to date, there was no statistically significant difference in the neurodevelopmental outcome at 18 to 24 months of age. Even though not statistically Newborn frontal horn cysts S Unger et al significant, infants with FHC were more likely to have abnormalities in the domain of fine and gross motor abnormalities, problem-solving and hearing loss. No differences in maternal and neonatal characteristics were noted that could have attributed to this difference. In our series, the infants did not have any additional findings of intrauterine infection and were not routinely tested to rule out an infectious etiology. Our findings regarding long-term outcome are consistent with the only other case-control study by Wong et al. 11 They reported no difference in motor and psychometric assessment at follow-up when controlled for GA, BW and sex in eight infants each in the index and control groups. Our study provides additional information on neurodevelopmental outcome of 16 infants each with and without FHC. It is reassuring to note that the presence of FHC did not alter the prognosis and therefore should be considered to be a benign condition. This information can be used to counsel parents who are often quite concerned with the findings on CUS. There was no long-term follow-up for 14 subjects (1 infant lost to follow-up and 13 did not fulfill the eligibility criteria as they were >32 weeks GA). Therefore, we cannot comment on the neurodevelopmental outcome for these larger babies.
However it is important to recognize that frontal lobe functions are not adequately tested using the ASQ and BSID II. Tests for executive functioning are now incorporated into new version of BSID (version III) and future studies on infants with and without FHC may be considered using the revised version. In addition, longer-term follow-up (school age) may be required to detect subtle differences in these infants.
Frontal horn cysts are classically described as thin-walled fluidfilled cysts adjacent to the superolateral margin of the frontal horn of the lateral ventricles. In our series the lesions noted on the CUS were typical in appearance and location and in all except two cases on subsequent scans. The differential diagnosis of intracranial cystic lesions in newborn include cavum septum pellucidum, cavum vergae and cavum veli interpositi, which are considered to be normal variants, cysts secondary to hemorrhagic or infectious etiology, developmental anomalies such as cisterna magna and lesions secondary to ischemic insults (PVL). 17 These lesions can be differentiated with the use of CUS and other neuroimaging modalities including magnetic resonance imaging and computerized tomography. 17 The most important differential diagnosis that should be considered when FHC is diagnosed is PVL as its presence is associated with adverse neurological outcome. On ultrasound, PVL commences as hyperechoic areas detected on the initial scan in the periventricular area (peritrigonal), and in the area anterior and lateral to the frontal horn. These regions then evolve into multiple, septated cysts 1 to 4 weeks later and result in white matter necrosis and cerebral atrophy. When detected on CUS, it is considered to be the most predictive marker for cerebral palsy. 17 This finding is distinct from FHC where the cysts are located at the superolateral angle of the frontal horn of the lateral ventricles, in contrast to PVL where the cystic lesions extend in the periventricular area.
The possible etiology for FHC has been widely speculated. A benign possibility is that these may be a normal variant whereas a more significant etiology is that FHC may be the sequelae of an ischemic insult with secondary germinolysis. One study reports the histopathology of FHC from post-mortem examinations. 5 There was no evidence of hemorrhagic or ischemic changes but rather the cyst was lined with neuroblasts with occasional blepharoplasts on the surface, suggesting an ependymal origin. The authors speculate that the FHC may originate as a diverticulum from the frontal horn of the ventricle, which in fetal life is secretory and later in gestation atrophies leading to cyst shrinkage. To date there has not been a genetic etiology identified for FHC but it is interesting to note the high rate of FHC in multiples for which the finding was concordant between siblings 75% of the time.
Conclusion
Head ultrasound scanning is now a routine practice in neonatal units, however the widespread use of this technology has lead to the discovery of cranial lesions for which the pathogenesis and outcome are unknown. As lesions on CUS may have significant sequelae for a patient and their family, it behooves their care providers to endeavor to understand the importance of these lesions. We document an incidence of FHC of 1% in the p32 weeks GA infant. At this point, these lesions do not appear to convey an increased risk for adverse neurodevelopmental outcome.
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